Form 13-F position report

SPRINGWORKS THERAPEUTICS IN

Reported by MORGAN STANLEY

SWTX CUSIP 85205L107 Manager CIK 0000895421

Reported 0 shares, down 1,247,783 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 25 Through Q3 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 5471000
2022-03-31 8460000
2022-06-30 12254000
2022-09-30 21557000
2022-12-31 9615532
2023-03-31 8440274
2023-06-30 8937718
2023-09-30 12206480
2023-12-31 20829253
2024-03-31 28599894
2024-06-30 12284955
2024-09-30 46093873
2024-12-31 72161591
2025-03-31 39521757
2025-06-30 58633345
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for SPRINGWORKS THERAPEUTICS IN held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -1,247,783 (-100.0%) 0 $0 2025-11-14
Q2 2025 Added 1,247,783 +352,208 (39.3%) < 0.01% $58,633,345 2025-08-15
Q1 2025 Reduced 895,575 -1,101,701 (-55.2%) < 0.01% $39,521,757 2025-05-15
Q4 2024 Added 1,997,276 +558,641 (38.8%) < 0.01% $72,161,591 2025-02-14
Q3 2024 Added 1,438,635 +1,112,516 (341.1%) < 0.01% $46,093,873 2024-11-14
Q2 2024 Reduced 326,119 -254,943 (-43.9%) < 0.01% $12,284,955 2024-08-14
Q1 2024 Added 581,062 +10,398 (1.8%) < 0.01% $28,599,894 2024-05-15
Q4 2023 Added 570,664 +42,702 (8.1%) < 0.01% $20,829,253 2024-02-13
Q3 2023 Added 527,962 +187,088 (54.9%) < 0.01% $12,206,480 2023-11-15
Q2 2023 Added 340,874 +12,969 (4.0%) < 0.01% $8,937,718 2023-08-14
Q1 2023 Reduced 327,905 -41,781 (-11.3%) < 0.01% $8,440,274 2023-05-15
Q4 2022 Reduced 369,686 -385,931 (-51.1%) < 0.01% $9,615,532 2023-02-14
Q3 2022 Added 755,617 +257,965 (51.8%) < 0.01% $21,557,000 2022-11-14
Q2 2022 Added 497,652 +347,754 (232.0%) < 0.01% $12,254,000 2022-08-15
Q1 2022 Added 149,898 +61,623 (69.8%) < 0.01% $8,460,000 2022-05-13
Q4 2021 Reduced 88,275 -24,961 (-22.0%) < 0.01% $5,471,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

220 managers reported SPRINGWORKS THERAPEUTICS IN for Q3 2025.

Managers reporting SPRINGWORKS THERAPEUTICS IN in Q3 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
DekaBank Deutsche Girozentrale Unchanged 40,000 0 < 0.01% $2,156,000 20 qtrs
ADVISOR GROUP HOLDINGS INC Reduced 83 -2,183 < 0.01% $3,899 19 qtrs
HUNTINGTON NATIONAL BANK Reduced 1 -442 < 0.01% $47 6 qtrs
SIGNATUREFD LLC Reduced 0 -134 0 $0 15 qtrs
PRINCIPAL SECURITIES INC Reduced 0 -8 0 $0 8 qtrs
Walleye Capital LLC Reduced 0 -5,882 0 $0 10 qtrs
Squarepoint Ops LLC Reduced 0 -204,271 0 $0 9 qtrs
ADAR1 Capital Management LLC Reduced 0 -24,082 0 $0 5 qtrs
PNC FINANCIAL SERVICES GROUP INC Reduced 0 -4,065 0 $0 13 qtrs
AlphaQuest LLC Reduced 0 -1,957 0 $0 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2025
Filed
November 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.